Matching articles for "Leqembi Iqlik"
In Brief: Subcutaneous Lecanemab (Leqembi Iqlik) for Initial Treatment of Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics • September 14, 2026; (Issue 1763)
The FDA has approved Leqembi Iqlik, the subcutaneous
(SC) formulation of the amyloid beta-directed monoclonal
antibody lecanemab, for once-weekly initiation dosing in
patients with Alzheimer's disease (AD)....
The FDA has approved Leqembi Iqlik, the subcutaneous
(SC) formulation of the amyloid beta-directed monoclonal
antibody lecanemab, for once-weekly initiation dosing in
patients with Alzheimer's disease (AD). The SC formulation
was previously approved only for maintenance treatment
in patients who had received IV lecanemab for at least
18 months.